Emerging trends in lung cancer research
Lung cancer continues to be a leading cause of cancer-related deaths globally, driving active research into new treatments and diagnostic methods. Recent advancements in lung cancer research have remodeled diagnosis, therapy, and prevention approaches.
This article focuses on these developments, highlighting the importance of early detection, treatment innovations, emerging therapies, and the role of artificial intelligence (AI) and machine learning (ML).
Why is early detection important?
Early detection of lung cancer significantly improves survival rates; many studies demonstrated that when lung cancer is diagnosed at an early stage, the five-year survival rate can be as high as 65%, compared to only 5% for advanced-stage lung cancer1. It allows for less aggressive treatments, reducing side effects and improving the patient's quality of life.
Recent screening technologies and methodologies innovations have augmented the ability to detect lung cancer at earlier, more treatable stages. Despite these benefits, only 16% of lung cancer cases are diagnosed at an early stage, highlighting the need for increased awareness and access to screening programs2.
Low-dose CT scans: Low-dose computed tomography (CT) scans are a noninvasive method that detects small nodules that may indicate early-stage lung cancer, enabling timely intervention3. They have become a cornerstone in lung cancer screening, particularly for high-risk populations such as heavy smokers. Studies have shown that low-dose CT scans can reduce lung cancer mortality by 20% when compared to chest X-rays.
Biomarkers: Biomarkers are essential for the early diagnosis of lung cancer. Liquid biopsy techniques, which include circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), and tumor-educated platelets (TEPs), provide noninvasive methods for detecting lung cancer at an early stage. These biomarkers allow for continuous monitoring and offer valuable insights into the progression of the disease and the patient's response to treatment, significantly improving patient outcomes4.
How has treatment advanced?
Substantial progress in lung cancer treatment has been made in recent years, with new therapies offering upgraded efficacy and reduced side effects.
Targeted therapy: Targeted therapies have improved the treatment of non-small cell lung cancer (NSCLC), the most prominent type of lung cancer, which occurs when abnormal cells form and multiply in the lungs. Tyrosine kinase inhibitors (TKIs) target specific genetic mutations, such as EGFR and ALK, that drive cancer growth. These therapies have shown remarkable success in shrinking tumors and prolonging survival in patients with these mutations. For example, osimertinib, a third-generation EGFR TKI, has demonstrated superior efficacy in treating EGFR-mutant NSCLC5.
Immunotherapy: Immunotherapy has surfaced as a powerful tool in the fight against lung cancer. Immune checkpoint inhibitors, such as pembrolizumab and nivolumab, enhance the body's immune response against cancer cells. These drugs have shown significant benefits in treating advanced NSCLC, leading to durable responses and improved survival rates6.
Combination therapies: Combining different treatment modalities, such as targeted therapy, immunotherapy, and chemotherapy, has shown potential in improving health results. For instance, combining TKIs with immune checkpoint inhibitors can overcome resistance mechanisms and enhance treatment efficacy. Active clinical trials are investigating multiple combination strategies to optimize treatment regimens7.
How are emerging therapies transforming lung cancer treatment?
Emerging therapies are continually being investigated to boost lung cancer treatment.
Nanoparticles: Nanotechnology offers new solutions that improve drug delivery and reduce side effects. Numerous nanoparticles, such as liposomes, polymeric micelles, and dendrimers, have been developed to improve the therapeutic index of anticancer drugs. These nanoparticles can encapsulate drugs, ensuring controlled release and reduced toxicity8.
Bispecific antibodies: Bispecific antibodies, such as amivantamab, are designed to target two different antigens simultaneously. Amivantamab targets both EGFR and MET, making it effective against NSCLC with EGFR exon 20 insertion mutations. Clinical trials have shown promising results, with significant tumor shrinkage and prolonged progression-free survival9.
Antibody-drug conjugates (ADCs): ADCs are a novel class of targeted therapies that deliver cytotoxic drugs directly to cancer cells. Trastuzumab deruxtecan, an ADC targeting HER2, has shown efficacy in HER2-mutant NSCLC. Other ADCs targeting TROP2, HER3, and MET are also being investigated in clinical trials, demonstrating encouraging results10.
What role do AI and ML play?
AI and ML are dramatically impacting lung cancer research, diagnosis, and treatment. These technologies are being used to analyze vast amounts of data from medical imaging, genomics, and clinical records.
Early detection: AI algorithms analyze low-dose CT scans with high precision, identifying potential cancerous lesions that human radiologists might miss. As mentioned above, this early detection is crucial for improving survival rates2,11.
Diagnostic accuracy: AI and ML models can process immense amounts of data to provide comprehensive diagnostic insights. For example, AI can detect subtle patterns in CT scans that indicate early-stage lung cancer, reducing false positives and negatives12. Studies suggested that the accuracy of the ML algorithms varied between 77.8% and 100%, and the AI architectures distinguished between malignant and benign lesions, successfully identifying small-cell lung cancer (SCLC) and NSCLC13.
Personalized treatment: AI-driven tools help tailor treatment plans based on individual patient profiles. They can also recommend the most effective therapies by analyzing genetic mutations and other biomarkers, enhancing treatment outcomes14.
What does the future hold for lung cancer research?
The future of lung cancer research is promising, with significant advancements on the horizon. Global collaboration is imperative, and investment in innovative technologies is accelerating progress. By continuing to focus on areas like early detection methods, immunotherapies, and targeted treatments, lung cancer research is poised to significantly enhance patient care and reduce the global burden of this disease.
References
1. Cancer Research UK. Lung cancer survival. https://www.cancerresearchuk.org/about-cancer/lung-cancer/survival (2023).
2. Babar, L., et al. Lung Cancer Screening. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK536404/ (2023).
3. Lancaster, H. L., et al. Low-dose computed tomography lung cancer screening: Clinical evidence and implementation research. J. Intern. Med. 292, 68-80 (2022).
4. Ren, F., Fei, Q., Qiu, K., et al. Liquid biopsy techniques and lung cancer: diagnosis, monitoring, and evaluation. J. Exp. Clin. Cancer Res. 43, 96 (2024).
5. Li, S., et al. Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer. Cancers 15, 2899 (2023).
6. Liu, B., Zhou, H., Tan, L., et al. Exploring treatment options in cancer: tumor treatment strategies. Sig. Transduct. Target Ther. 9, 175 (2024).
7. Garg, P., et al. Next-Generation Immunotherapy: Advancing Clinical Applications in Cancer Treatment. J. Clin. Med. 13, 6537 (2024).
8. Holder, J.E. et al. The use of nanoparticles for targeted drug delivery in non-small cell lung cancer. Front. Oncol. 13, 1154318 (2023).
9. Vyse, S., Huang, P. H. Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer. Expert Rev. Anticancer Ther. 22, 3-16 (2022).
10. Desai, A., et al. Association of Antibody-Drug Conjugate (ADC) Target Expression and Interstitial Lung Disease (ILD) in Non-Small-Cell Lung Cancer (NSCLC): Association or Causation or Neither? Cancers 16, 3753 (2024).
11. Cellina, M., et al. Artificial Intelligence in Lung Cancer Screening: The Future Is Now. Cancers 15, 4344 (2023).
12. Gandhi, Z., et al. Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes. Cancers 15, 5236 (2023).
13. Pacurari, A.C., et al. Diagnostic Accuracy of Machine Learning AI Architectures in Detection and Classification of Lung Cancer: A Systematic Review. Diagnostics (Basel, Switzerland) 13, 2145 (2023).
14. Huang, D., et al. Artificial intelligence in lung cancer: current applications, future perspectives, and challenges . Front. Oncol. 14, 1486310 (2024).